Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GDRX Stock Forecast 2025-2026
$2.72
Current Price
$945.06M
Market Cap
Buy 8
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to GDRX Price Targets
+157.4%
To High Target of $7.00
+83.8%
To Median Target of $5.00
+10.3%
To Low Target of $3.00
GDRX Price Momentum
+1.5%
1 Week Change
-12.5%
1 Month Change
-45.2%
1 Year Change
-41.5%
Year-to-Date Change
-53.2%
From 52W High of $5.81
+4.2%
From 52W Low of $2.61
📊 TOP ANALYST CALLS
Did GDRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if GoodRx is one of their latest high-conviction picks.
Latest GDRX Stock Price Targets & Analyst Predictions
Based on our analysis of 26 Wall Street analysts, GDRX has a bullish consensus with a median price target of $5.00 (ranging from $3.00 to $7.00). The overall analyst rating is N/A (N/A/10). Currently trading at $2.72, the median forecast implies a 83.8% upside. This outlook is supported by 8 Buy, 5 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Stan Berenshteyn at Wells Fargo, projecting a 157.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GDRX Analyst Ratings
8
Buy
5
Hold
1
Sell
GDRX Price Target Range
Low
$3.00
Average
$5.00
High
$7.00
Current: $2.72
Latest GDRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GDRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 11, 2025 | JP Morgan | Lisa Gill | Overweight | Maintains | $5.00 |
| Nov 10, 2025 | TD Cowen | Charles Rhyee | Buy | Maintains | $6.00 |
| Nov 6, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $4.00 |
| Nov 6, 2025 | Mizuho | Steven Valiquette | Neutral | Maintains | $4.00 |
| Aug 11, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $4.25 |
| May 13, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $5.25 |
| May 9, 2025 | Goldman Sachs | Eric Sheridan | Neutral | Maintains | $5.00 |
| Apr 29, 2025 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $7.00 |
| Apr 10, 2025 | Truist Securities | Jailendra Singh | Hold | Maintains | $5.50 |
| Feb 28, 2025 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $8.00 |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $6.25 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $6.00 |
| Dec 17, 2024 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $6.00 |
| Nov 13, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $7.00 |
| Nov 11, 2024 | Barclays | Stephanie Davis | Overweight | Maintains | $6.00 |
| Aug 16, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $10.00 |
| Aug 9, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $10.00 |
| Aug 9, 2024 | UBS | Kevin Caliendo | Neutral | Maintains | $8.50 |
| Jun 10, 2024 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $9.50 |
| May 23, 2024 | RBC Capital | Mark Mahaney | Outperform | Upgrade | $10.00 |
GoodRx Holdings Inc. (GDRX) Competitors
The following stocks are similar to GoodRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GoodRx Holdings Inc. (GDRX) Financial Data
GoodRx Holdings Inc. has a market capitalization of $945.06M with a P/E ratio of 33.9x. The company generates $800.65M in trailing twelve-month revenue with a 4.0% profit margin.
Revenue growth is +0.4% quarter-over-quarter, while maintaining an operating margin of +7.5% and return on equity of +4.9%.
Valuation Metrics
Market Cap
$945.06M
Enterprise Value
$1.19B
P/E Ratio
33.9x
PEG Ratio
-0.3x
Price/Sales
1.2x
Growth & Margins
Revenue Growth (YoY)
+0.4%
Gross Margin
+93.2%
Operating Margin
+7.5%
Net Margin
+4.0%
EPS Growth
-71.8%
Financial Health
Cash/Price Ratio
+29.6%
Current Ratio
3.1x
Debt/Equity
90.7x
ROE
+4.9%
ROA
+5.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
GoodRx Holdings Inc. (GDRX) Business Model
About GoodRx Holdings Inc.
What They Do
Digital platform for affordable prescription medications.
Business Model
GoodRx generates revenue by partnering with pharmacies and pharmaceutical companies to offer discounts and coupons to consumers. The company earns fees for each transaction facilitated through its platform, making it financially viable while helping users save on medication costs.
Additional Information
GoodRx significantly impacts the healthcare market by providing transparency in drug pricing and addressing high medication costs for uninsured individuals. The company is based in Santa Monica, California, and serves a critical role in enhancing accessibility to affordable healthcare solutions.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
738
CEO
Ms. Wendy Barnes
Country
United States
IPO Year
2020
Website
www.goodrx.comGoodRx Holdings Inc. (GDRX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside?
Hims & Hers and GoodRx are reshaping virtual care, but which one leads in platform strategy and patient engagement? Let's dive in.
Nov 28, 2025
By Debanjana Dey
Analyst Blog
Latest News
Quick Summary
Hims & Hers and GoodRx are competing in the virtual care sector, focusing on platform strategy and patient engagement. Investors should monitor their developments for potential impacts.
Why It Matters
The competition between Hims & Hers and GoodRx in virtual care could impact market share, revenue growth, and investor confidence, influencing stock performance and investment strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
GoodRx announced the launch of "GoodRx for Weight Loss," a telemedicine service for weight management, and a $199 monthly cash price for Ozempic® in partnership with Novo Nordisk.
Why It Matters
GoodRx's initiatives to increase access to GLP-1 medications could drive higher usage and revenue, positively impacting stock performance and market position amid rising obesity treatment demand.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
GoodRx CEO Wendy Barnes noted a significant shift in prescription drug pricing, driven by the upcoming launch of TrumpRx, a government-run drug pricing website.
Why It Matters
The launch of TrumpRx could disrupt the prescription drug market, impacting pricing strategies and competition, directly affecting GoodRx's business model and stock performance.
Source: PYMNTS
Market Sentiment:
Positive
Quick Summary
GoodRx Holdings, Inc. will hold its Q3 2025 earnings call on November 5, 2025, at 8:00 AM EST, featuring key company executives and several financial analysts.
Why It Matters
The upcoming earnings call for GoodRx on November 5, 2025, will provide key insights into the company's financial health and performance, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Should You Buy GoodRx Stock?
1 month ago
Quick Summary
GoodRx (GDRX) is expanding, generating cash flow, and is currently trading at a significant valuation discount, making it a stock worth considering for investment.
Why It Matters
GoodRx's expansion, cash generation, and attractive valuation suggest potential for growth and profitability, making it a compelling opportunity for investors seeking value.
Source: Forbes
Market Sentiment:
Positive
GoodRx Reports Third Quarter 2025 Results
1 month ago
Quick Summary
GoodRx Holdings, Inc. reported Q3 2025 revenue of $196 million, with a net income of $1.1 million and an adjusted EBITDA of $66.3 million, reflecting a margin of 33%.
Why It Matters
GoodRx's Q3 2025 financial results show stable revenue and positive adjusted income, indicating operational efficiency and potential for future growth, which could affect stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About GDRX Stock
What is GoodRx Holdings Inc.'s (GDRX) stock forecast for 2026?
Based on our analysis of 26 Wall Street analysts, GoodRx Holdings Inc. (GDRX) has a median price target of $5.00. The highest price target is $7.00 and the lowest is $3.00.
Is GDRX stock a good investment in 2026?
According to current analyst ratings, GDRX has 8 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $2.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GDRX stock?
Wall Street analysts predict GDRX stock could reach $5.00 in the next 12 months. This represents a 83.8% increase from the current price of $2.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is GoodRx Holdings Inc.'s business model?
GoodRx generates revenue by partnering with pharmacies and pharmaceutical companies to offer discounts and coupons to consumers. The company earns fees for each transaction facilitated through its platform, making it financially viable while helping users save on medication costs.
What is the highest forecasted price for GDRX GoodRx Holdings Inc.?
The highest price target for GDRX is $7.00 from Stan Berenshteyn at Wells Fargo, which represents a 157.4% increase from the current price of $2.72.
What is the lowest forecasted price for GDRX GoodRx Holdings Inc.?
The lowest price target for GDRX is $3.00 from at , which represents a 10.3% increase from the current price of $2.72.
What is the overall GDRX consensus from analysts for GoodRx Holdings Inc.?
The overall analyst consensus for GDRX is bullish. Out of 26 Wall Street analysts, 8 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $5.00.
How accurate are GDRX stock price projections?
Stock price projections, including those for GoodRx Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 9, 2025 2:45 AM UTC